422 related articles for article (PubMed ID: 25917369)
41. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.
Lisinski A; Hieronymus F; Näslund J; Nilsson S; Eriksson E
Neuropsychopharmacology; 2020 Feb; 45(3):553-560. PubMed ID: 31521062
[TBL] [Abstract][Full Text] [Related]
42. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
Sir A; D'Souza RF; Uguz S; George T; Vahip S; Hopwood M; Martin AJ; Lam W; Burt T
J Clin Psychiatry; 2005 Oct; 66(10):1312-20. PubMed ID: 16259546
[TBL] [Abstract][Full Text] [Related]
43. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
[TBL] [Abstract][Full Text] [Related]
45. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
46. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
47. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
Vis PM; van Baardewijk M; Einarson TR
Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.
Papakostas GI; Trivedi MH; Alpert JE; Seifert CA; Krishen A; Goodale EP; Tucker VL
J Psychiatr Res; 2008 Jan; 42(2):134-40. PubMed ID: 17631898
[TBL] [Abstract][Full Text] [Related]
49. Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Zhou J; Wang X; Feng L; Xiao L; Yang R; Zhu X; Shi H; Hu Y; Chen R; Boyce P; Wang G
BMC Psychiatry; 2021 May; 21(1):260. PubMed ID: 34011310
[TBL] [Abstract][Full Text] [Related]
50. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
de Silva VA; Hanwella R
Int Clin Psychopharmacol; 2012 Jan; 27(1):8-16. PubMed ID: 21971532
[TBL] [Abstract][Full Text] [Related]
52. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
Shelton CI
J Clin Psychiatry; 2004; 65 Suppl 17():29-33. PubMed ID: 15600379
[TBL] [Abstract][Full Text] [Related]
53. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
54. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
55. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
56. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
[TBL] [Abstract][Full Text] [Related]
57. Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials.
Gibiino S; Marsano A; Serretti A
Int J Neuropsychopharmacol; 2014 Jan; 17(1):1-8. PubMed ID: 23953038
[TBL] [Abstract][Full Text] [Related]
58. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
Kennedy SH; Eisfeld BS; Dickens SE; Bacchiochi JR; Bagby RM
J Clin Psychiatry; 2000 Apr; 61(4):276-81. PubMed ID: 10830148
[TBL] [Abstract][Full Text] [Related]
59. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors.
Papakostas GI; Nutt DJ; Hallett LA; Tucker VL; Krishen A; Fava M
Biol Psychiatry; 2006 Dec; 60(12):1350-5. PubMed ID: 16934768
[TBL] [Abstract][Full Text] [Related]
60. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study.
Posternak MA; Zimmerman M
J Clin Psychiatry; 2005 Jun; 66(6):705-7. PubMed ID: 15960562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
